title: Eicosanoids as a new class of ocular hypotensive agents. 3. Prostaglandin A2-1-isopropyl ester is the most potent reported hypotensive agent on feline eyes.
abstract: It has been shown that prostaglandin A2 (PGA2) is a more potent ocular hypotensive agent in cats than other PG free acids. We report here that significant IOP reduction can be achieved in normotensive cat eyes with the use of even lower doses of PGA2-1-isopropyl ester (PGA2-IE) than with PGA2, PGF2 alpha-1-isopropyl ester (PGF2 alpha-IE), or any other known ocular hypotensive agent. Furthermore, single applications of 0.5 microgram of PGA2-IE maintain significant IOP reductions for at least 24 hr. This hypotensive effect is enhanced during the first 3-5 days of daily treatment. Significant IOP reductions were maintained for several months as long as PGA2-IE was applied daily or at least once every 48 hr. None of the cats manifested signs of discomfort in response to treatment with doses ranging from 0.10 to 1.25 micrograms of PGA2-IE. Moreover, the extent of anterior chamber flare was less than that typically observed after the topical application of hypotensive doses of PGE2, PGD2, PGF2 alpha, or the esters or tromethamine salt of PGF2 alpha. Although it is possible that the human eye would respond differently to PGs of the A type, the results of these studies suggests that PGA2-IE or other esters of derived PGs of the A type, and probably the B type, may offer significant therapeutic advantages over the PGF2 alpha tromethamine salt and PGF2 alpha-IE, which have been shown to exert significant hypotensive effects on normal and glaucomatous human eyes.
authors.affiliation: Department of Ophthalmology, College of Physicians and Surgeons, Columbia University, New York, NY 10032.
authors.forename: L Z
authors.initials: LZ
authors.lastname: Bito
authors.forename: O C
authors.initials: OC
authors.lastname: Miranda
authors.forename: M R
authors.initials: MR
authors.lastname: Tendler
authors.forename: B
authors.initials: B
authors.lastname: Resul
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002415:Cats; D015237:Dinoprost / Q000031:analogs & derivatives / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy*; D011454:Prostaglandins A / Q000627:therapeutic use*; D011455:Prostaglandins A, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D011454:Prostaglandins A; D011455:Prostaglandins A, Synthetic; D011461:Prostaglandins F, Synthetic; C064125:prostaglandin A2 isopropyl ester; C041158:prostaglandin F2 isopropyl ester; D015237:Dinoprost